Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma
In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surgery alone.